8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 10, 2022

ALIMERA SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-34703		20-0028718
(State or other Jurisdiction of Incorporation)	(Commission File Number)		(IRS Employer Identification No.)
6310 Town Square, Suite 400 Alpharetta, Georgia		30005
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (678) 990-5740

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	ALIM	The Nasdaq Stock Market LLC (Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

#x200e

Item 2.02. Results of Operations and Financial Condition.

On November 14, 2022, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the three and nine months ended September 30, 2022 as well as a corporate update. On November 14, 2022 at 9:00 A.M. ET, Alimera will host a conference call and a live webcast on the Investor Relations section of its corporate website at www.alimerasciences.com. During the conference call, Alimera’s executives will discuss the company’s financial results for the three and nine months ended September 30, 2022 and provide an update on corporate developments. The full text of the press release, which includes information regarding Alimera’s use of non-GAAP financial measures, is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Various statements made during the conference call and webcast will or may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change these expectations, and could cause actual results to differ materially from those projected in these forward-looking statements. Meaningful factors that could cause actual results to differ include, but are not limited to, uncertainties associated with (a) governmental orders and policies adopted by healthcare facilities to address the COVID-19 pandemic; (b) the possible resurgence of the pandemic in certain markets; (c) the effects of the emergence of COVID-19 variants that increase the transmissibility of the coronavirus, particularly if those variants are or become more deadly; (d) the success or failure of the continued vaccine campaigns in Alimera’s markets; and (e) whether and when Alimera’s international operations will return to their prior growth trajectory in certain key markets, particularly Germany; as well as the other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2021 and Alimera’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022, which are on file with the SEC and are available on Alimera’s website and the SEC’s website at http://www.sec.gov. Additional factors will also be described in those sections of Alimera’s Quarterly Report on Form 10-Q for the third quarter of 2022, to be filed with the SEC today.

In addition to the risks described above and in Alimera’s reports and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera’s results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. All forward-looking statements contained in the conference call and webcast and in the press release are expressly qualified by the cautionary statements contained or referred to herein and therein. These forward-looking statements speak only as of the date of the conference call and webcast and the press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

The information in Item 2.02 of this Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

As previously reported, J. Philip Jones resigned as Chief Financial Officer of Alimera Sciences, Inc. (the “Company”), effective November 28, 2022. On November 10, 2022, the Company’s board of directors determined that upon Mr. Jones’ resignation on November 28, 2022, Richard S. Eiswirth, Jr., the Company’s current President and Chief Executive Officer, will serve as the Company’s interim Chief Financial Officer and will assume the roles of principal financial officer and principal accounting officer. The Company is conducting a search for a permanent Chief Financial Officer.

Mr. Eiswirth, age 53, has served as the Company’s Chief Executive Officer since January 2019. Mr. Eiswirth had previously served as the Company’s President and Chief Financial Officer since January 2016. Before that, he served as the Company’s Chief Operating Officer and Chief Financial Officer from August 2010 until December 2015 and as the Company’s Chief Financial Officer from October

2

2005 to August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, a privately held company engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a privately held financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a public company that provided of Internet banking solutions to community banks, from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth served as a director of Celtaxsys Inc., a privately held biotechnology company, from 2015 to 2020, where he also chaired the audit committee and served as a member of the compensation committee. Mr. Eiswirth previously served from 2006 to 2012 as a director of Jones Soda Co., a Seattle, Washington-based public beverage company, and served as chairman, audit committee chairman and member of the compensation committee during his tenure. He also served from 2003 to 2006 as director and audit committee chairman of Color Imaging, Inc., a Norcross, Georgia based public manufacturer of printer and copier supplies. Mr. Eiswirth was previously a Certified Public Accountant in Georgia. Mr. Eiswirth holds a B.A. in accounting from Wake Forest University.

Mr. Eiswirth has no family relationship with any director or executive officer of the Company and has not been a party to any transaction with the Company that is required to be reported in this Current Report on Form 8-K.

As of the date of this report, no new compensatory arrangements have been entered into in connection with the appointment of Mr. Eiswirth as interim Chief Financial Officer.

Item 7.01. Regulation FD.

The conference call and webcast, and the press release, include or will include non-GAAP financial measures. A reconciliation of these non-GAAP financial measures to the comparable measures calculated and presented in accordance with GAAP is included in Alimera’s press release issued November 14, 2022 and attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K under Item 7.01 is being “furnished” and not “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under such section. Furthermore, such information shall not be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, unless specifically identified as being incorporated therein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits

Exhibit No.	Description
99.1	Press Release of Alimera Sciences, Inc. dated November 14, 2022
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

‎

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALIMERA SCIENCES, INC.
Dated: November 14, 2022	By:	/s/ J. Philip Jones
	Name:	J. Philip Jones
	Title:	Chief Financial Officer

4

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Alimera Sciences Announces ThirdQuarter 2022 Financial Results

· Consolidated Net Product Revenue of $13.6 Million,up 11%vs. ThirdQuarter of 2021

o Net Product Revenue Was Unfavorably Impacted by Approximately $800,000in Foreign Currency Fluctuations

· Excluding Fluctuations in Foreign CurrencyExchange Rates,Consolidated Net Product Revenue Would Have Been $14.4  Million, up 18% vs. Third Quarter of 2021

· Record Third Quarter U.S. Revenue and End User Demand up 27% vs. Third Quarter of 2021

· Record International End User Demand up 27% vs. Third Quarter of 2021

· Company Entered into Agreement for Radiation Retinopathy Trial with the DRCR Retina Network

ATLANTA, November 14,  2022 --Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the thirdquarter of 2022. Alimera will host a conference call today at 9:00 a.m.  EST to discuss these results.

“The third quarter delivered another strong performance for ILUVIEN global end user demand with our U.S. Segment and our International Segment both up 27% over the same period a  year ago,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer. “2022 has been a record performance for end user demand in both our U.S. and International Segments for the nine months ended September 30.  This has also been a very productive year for our geographic expansion strategy, as we obtained reimbursement in six European countries for our non-infectious uveitis indication,  driving strong performance in our French and Spanish markets specifically. We are alsovery excited to have announced our agreement to work with the DRCR Retina Network in evaluating ILUVIEN’s potential to reduce the incidence and recurrence of radiation retinopathy, another unmet need affecting the retina.”

ThirdQuarter 2022Financial Results

Consolidated Net Revenue

Consolidated net revenue increased 11%  to approximately $13.6million for Q3 2022 compared to$12.2million for Q3 2021.  Fluctuations inforeign currency exchange rates

since Q3 2021 have unfavorably impacted our Q3 2022 international revenue byapproximately $800,000, due to the weakened Euro and British Pound Sterling over the past year.Excluding fluctuations in foreign currency exchange rates,  revenue increased by approximately 18%  overQ3 2021.Adjustments in net product revenue to exclude fluctuations in foreign currency exchange rates result in a non-GAAP financial measure. Please refer to the section of this press release entitled “Non-GAAP Financial Measures” and the table entitled “Reconciliation of GAAP Net Product Revenue to Non-GAAP Adjusted Net Product Revenue.”

U.S. Net Revenue

U.S. netproductrevenueincreased 27% to approximately $8.9million for Q3  2022compared to $7.0 million for Q32021. The increase was primarily due to investment in our sales, marketing, scientific and medical programs, which drove greater utilization of ILUVIEN.  End user demand, which represents units purchased by physicians and pharmacies from our distributors, increased 27% to 1,061unitsduring Q32022,a record third quarter for our U.S. segment,  compared to 837units during Q32021.

International Net Revenue

International net product revenue decreased by approximately $500,000, or approximately 10%, to approximately $4.7 million for Q3 2022, compared to approximately $5.2 million for Q3 2021. The decreasein international net product revenue among our direct and distributor markets in Europe was primarily the result of deteriorating foreign exchange rates for the Euro and British Pound Sterling, which had an unfavorable impact on our international revenue of approximately $800,000 in Q3 2022. Excluding fluctuations in foreign currency exchange rates,  revenue increased by approximately 6%  overQ3 2021. Other factors contributing to the decrease ininternational product revenue were lower sales in certain markets in Europe and the timing of orders from ourinternational distributors, notwithstanding a 27% increase in end user demand from 1,018 units in Q3 2021 to 1,292 units in Q3 2022.

Operating Expenses

Total operating expenses were approximately $15.0million for Q32022, compared to approximately $12.5million for Q32021.  

This increase was composed of a)cost increases in research, development and medical affairs associated with transfer of our inserter component manufacturing,  NEW DAY Study and travel,  b) added sales and marketing expense associated with the directtopatient marketing campaign and increased personnel costs, and c)increased general and administrative costs tied to a $560,000 recovery of VAT refunds in2021 that did not recur in 2022.

NetLoss and Adjusted EBITDA

Net lossfor Q32022was $5.3million, compared to a net lossof approximately $4.2million for Q32021.  

“Adjusted EBITDA,” a non-GAAP financial measure, wasapproximately $(2.5)million for Q32022, compared to Adjusted EBITDA of approximately$(1.1)million for Q32021.  For purposes of this press release, “Adjusted EBITDA” is defined as earnings before interest, taxes, depreciation, amortization, stock-based compensation expenses, net unrealized gains and losses from foreign currency exchange transactions, losses on extinguishment of debt, severance expenses and change in fair value of warrant asset. Please refer to the section of this press release entitled “Non-GAAP Financial Measures” and the table entitled “Reconciliation of GAAP Net Income or Loss to Non-GAAP Adjusted EBITDA.”

Net Lossper Share

Basic and diluted net lossper share for Q32022was approximately$(0.75)compared to basic and diluted net lossper share of $(0.60) for Q32021.

Cash and Cash Equivalents

On September30,  2022, Alimera had cash and cash equivalents of approximately $5.5million dollars, compared to $7.9million in cash and cash equivalents on June 30,2022.

ALIM Call Details - Q32022 Financial Results Conference Call

Conference Call to Be Held November 14, 2022

A live conference call will be hosted today November 14, 2022, at 9:00a.m.EST  by Rick Eiswirth, president and chief executive officer, and Phil Jones, chief financial officer, to discuss Alimera’s financial results and provide an update on corporate developments.  Please refer to the information below for conference call dial-in information and webcast registration.

Conference date:Monday,  November 14, 2022,9;00a.m.EST
Conference dial-in: 844-839-2190

International dial-in: 412-317-9583

Conference Call Name: Alimera Sciences (Nasdaq: ALIM) ThirdQuarter 2022Financial Results Conference Call
Conference Call Pre-registration: Participants are asked to pre-register for the call by navigating to:https://dpregister.com/sreg/10172804/f4f6c45000

Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

The conference call will also be available through a live webcast which is also available through the company’s website.

Live WebcastURL:

https://event.choruscall.com/mediaframe/webcast.html?webcastid=lcASYWZJ

A replay will be available on Alimera’s website, www.alimerasciences.com,  under “Investor Relations” one hour following the live call.

Conference Call replay: US Toll Free: 1-877-344-7529

International Toll: 1-412-317-0088

Canada Toll Free: 855-669-9658

Replay Access Code: 1728884

End Date: November 28,  2022

Webcast Replay End Date: February 14,  2023

About Alimera Sciences, Inc.

Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

Non-GAAP Financial Measures

This press release contains a discussion of non-GAAP financial measures, as defined in Regulation G promulgated under the Securities Exchange Act of 1934, as amended. Alimera reports its financial results in compliance with GAAP but believes that the non-GAAP financial measures of Adjusted EBITDA and adjusted net product revenue to exclude fluctuations in foreign currency exchange ratesprovide useful information to investors regarding Alimera’s operating performance.  Alimera uses each of these non-GAAP financial measuresin the management of its business. Accordingly, Adjusted EBITDA for the three months ended September30,  2022and 2021has been presented in certain instances excluding items identified in the reconciliations provided in the table entitled “Reconciliation of GAAP Net Income or Loss to Non-GAAP Adjusted EBITDA.” GAAP net income or loss is the most directly comparable GAAP financial measure to Adjusted EBITDA.  Further, net product revenue has been adjusted to exclude fluctuations in foreign currency exchange ratesfor the three months ended September30, 2022 and 2021. See the table entitled “Reconciliation of GAAP Net Product Revenue to Non-GAAP Adjusted Net Product Revenue.”GAAP net product revenue is the most directly comparable GAAP financial measure to adjusted net product revenue.

These non-GAAP financial measures, as presented, may not be comparable to similarly titled measures reported by other companies because not all companies calculate Adjusted EBITDA or adjust revenue for currency fluctuations in an identical manner. Therefore, these non-GAAP financial measuresare not necessarily accurate measures of comparison between companies.

The presentation of these non-GAAP financial measuresis not intended to be considered in isolation or as a substitute for guidance prepared in accordance with GAAP. The principal limitation of these non-GAAP financial measuresis that they exclude significant elements required by GAAP to be recorded in Alimera’s financial statements. In addition, these non-GAAP financial measuresare subject to inherent

limitations because they reflect the exercise of judgments by management in determining these non-GAAP financial measures.  

Forward Looking Statements

The conference call in which executives of Alimera will discuss this press release may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.Any such forward-looking statements will be based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change these expectations, and could cause actual results to differ materially from those projected in these forward-looking statements.

Meaningful factors that could cause actual results to differ include, but are not limited to, uncertainties associated with (a) governmental orders and policies adopted by healthcare facilities to address the COVID-19 pandemic; (b) the possible resurgence of the pandemic in certain markets; (c) the effects of the emergence of COVID-19 variants that increase the transmissibility of the coronavirus, particularly if those variants are or become more deadly; (d) the success or failure of the continued vaccine campaigns in Alimera’s markets; and (e) whether and when Alimera’s international operations will return to their prior growth trajectory in certain key markets, particularly Germany; as well as the other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2021 and Alimera’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022, which are on file with the SEC and are available on Alimera’s website and the SEC’s website at http://www.sec.gov. Additional factors will also be described in those sections of Alimera’s Quarterly Report on Form 10-Q for the third quarter of 2022 to be filed with the SEC today.

Alimera undertakes no obligation to publicly update or revise any of the forward-looking statements made in this press release, whether as a result of new information, future events or otherwise, except as required by law. Therefore, you should not rely on these forward-looking statements as representing Alimera’s views as of any date after today.

For investor inquiries:                                         For media inquiries:

Scott Gordon                                                          Jules Abraham

for Alimera Sciences                                              for Alimera Sciences
scottg@coreir.comjulesa@coreir.com

ALIMERA SCIENCES, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands)

	September 30,		December 31,
	2022		2021
	(In thousands, except share and per share data)
CURRENT ASSETS:
Cash and cash equivalents	$	5,514	$	16,510
Restricted cash		28		34
Accounts receivable, net		19,142		19,128
Prepaid expenses and other current assets		3,290		3,809
Inventory		1,786		2,679
Total current assets		29,760		42,160
NON-CURRENT ASSETS:
Property and equipment, net		2,446		2,783
Right of use assets, net		1,424		1,710
Intangible asset, net		9,446		10,897
Deferred tax asset		118		137
Warrant asset		235		833
TOTAL ASSETS	$	43,429	$	58,520
CURRENT LIABILITIES:
Accounts payable	$	8,706	$	8,706
Accrued expenses		3,661		3,617
Notes payable		21,316		—
Finance lease obligations		327		269
Total current liabilities		34,010		12,592
NON-CURRENT LIABILITIES:
Notes payable, net of discount		22,492		43,080
Other non-current liabilities		5,005		5,453
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ DEFICIT:
Preferred stock:
Series A Convertible Preferred Stock		19,227		19,227
Common stock		70		69
Additional paid-in capital		378,005		377,229
Accumulated deficit		(411,608)		(397,281)
Accumulated other comprehensive loss		(3,772)		(1,849)
TOTAL STOCKHOLDERS’ DEFICIT		(18,078)		(2,605)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	43,429	$	58,520

ALIMERA SCIENCES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 AND 2021

(In thousands, except share and per share data)

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2022		2021		2022		2021
	(In thousands, except share and per share data)
REVENUE:
PRODUCT REVENUE, NET	$	13,598	$	12,153	$	40,100	$	34,022
LICENSE REVENUE		—		—		—		11,048
NET REVENUE		13,598		12,153		40,100		45,070
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION		(2,006)		(1,689)		(5,852)		(5,064)
GROSS PROFIT		11,592		10,464		34,248		40,006
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES		4,483		3,278		11,998		10,058
GENERAL AND ADMINISTRATIVE EXPENSES		3,352		2,808		9,537		9,577
SALES AND MARKETING EXPENSES		6,504		5,751		20,222		15,900
DEPRECIATION AND AMORTIZATION		664		649		2,023		1,920
OPERATING EXPENSES		15,003		12,486		43,780		37,455
LOSS FROM OPERATIONS		(3,411)		(2,022)		(9,532)		2,551
INTEREST EXPENSE AND OTHER		(1,500)		(1,360)		(4,247)		(4,050)
UNREALIZED FOREIGN CURRENCY (LOSS) GAIN, NET		(67)		142		79		323
GAIN ON EXTINGUISHMENT OF DEBT		—		—		—		1,792
CHANGE IN FAIR VALUE OF WARRANT ASSET		(267)		(1,112)		(598)		(411)
NET (LOSS) INCOME BEFORE TAXES		(5,245)		(4,352)		(14,298)		205
INCOME TAX (PROVISION) BENEFIT		(12)		169		(29)		(471)
NET LOSS	$	(5,257)	$	(4,183)	$	(14,327)	$	(266)
NET LOSS PER SHARE — Basic and Diluted	$	(0.75)	$	(0.60)	$	(2.05)	$	(0.04)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic and Diluted		6,996,575		6,924,174		6,995,695		6,480,952

RECONCILIATION OF GAAP MEASURES TO NON-GAAP ADJUSTED MEASURES

(in thousands)

RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(unaudited)
GAAP NET LOSS	$	(5,257)	$	(4,183)	$	(14,327)	$	(266)
Adjustments to net loss:
Interest expense and other	1,500		1,360		4,247		4,050
Provision (benefit) for taxes	12		(169)		29		471
Depreciation and amortization	664		649		2,023		1,920
Stock-based compensation expenses	143		244		723		758
Unrealized foreign currency exchange loss (gain), net	67		(142)		(79)		(323)
Gain on extinguishment of debt	—		—		—		(1,792)
Change in fair value of warrant asset	267		1,112		598		411
Severance expenses	110		—		147		195
NON-GAAP ADJUSTED EBITDA	$	(2,494)	$	(1,129)	$	(6,639)	$	5,424

RECONCILIATION OF GAAP NET PRODUCT REVENUE TO NON-GAAP ADJUSTED NET PRODUCT REVENUE

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(unaudited)
GAAP NET PRODUCT REVENUE	$	13,598	$	12,153	$	40,100	$	34,022
Adjustment to net product revenue:
Foreign currency fluctuations, net	809		—		1,894		—
NON-GAAP ADJUSTED  NET PRODUCT REVENUE	$	14,407	$	12,153	$	41,994	$	34,022

XML

Document and Entity Information	Nov. 10, 2022
Document and Entity Information [Abstract]
Document Type	8-K
Document Period End Date	Nov. 10, 2022
Entity Registrant Name	ALIMERA SCIENCES, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-34703
Entity Tax Identification Number	20-0028718
Entity Address, Address Line One	6310 Town Square
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Alpharetta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30005
City Area Code	678
Local Phone Number	990-5740
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	ALIM
Security Exchange Name	NASDAQ
Emerging Growth Company	false
Entity Central Index Key	0001267602
Amendment Flag	false